# OnCo record nct04595565 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04595565/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04595565", "NCT04595565" ;
  schema:name "Sacituzumab Govitecan in Primary HER2-negative Breast Cancer"@en ;
  schema:alternateName "SASCIA"@en ;
  schema:description "A phase 3 trial of capecitabine, carboplatin, cisplatin and sacituzumab govitecan in triple-negative breast cancer, run by GBG Forschungs GmbH, active but no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04595565/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04595565> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/sacituzumab-govitecan/> .